Immutep banks $1.52 million French R&D tax credit as pipeline resets
What's the deal? ImmutepDealroom has a profile for this one. Try Dealroom →, a clinical-stage immunotherapy company, has received a non-dilutive cash grant of US$1.4M (around $1.52 million) from the French GovernmentDealroom has a profile for this one. Try Dealroom → through its Crédit d'Impôt Recherche (CIR) tax incentive. The payment reimburses eligible research spending from the 2025 calendar year.
How it works: The CIR refunds 30% of qualifying R&D costs. Immutep claims it through its French subsidiary, Immutep S.A.S., which runs a research lab in France. The money will fund work on its lead candidates eftilagimod alfa (efti) and IMP761.
Why it matters: This is routine runway support, not a new investment round, and it is consistent with Immutep's recurring use of the French scheme — it received about US$2.98M for 2024 activity. The company expects its cash to last into the first half of 2028.
The bigger picture: The credit lands during a difficult reset. In March 2026, Immutep discontinued its registrational Phase III efti lung-cancer trial, TACTI-004, after an interim futility analysis, and later repaid US$10 million of a US$20 million upfront payment to licensing partner Dr. ReddyDealroom has a profile for this one. Try Dealroom →'s.
Immutep reported a net loss of US$51.3M for fiscal 2026, up from US$39.7M the year before, and held US$41.2M in cash and US$3.36M in term deposits at June 30, 2026. The credit follows an US$556.5K rebate from Australia's R&D Tax Incentive, announced in September 2026.
The signal: Non-dilutive government funding across France, Australia, and Germany offers steady, if modest, support for Immutep's research. But the sums are small beside clinical-development needs and do little to resolve the uncertainty around efti's future.
Read more: kalkinemedia.com
Image credit: Generated with Gemini
